Table 2 Comparative clinico-pathological characteristics and risk group assignments in the study cohort between clinical based characterisation (DRE + systematic sampling only) versus MRI based characterisation (MRI staging and combined MRI targeted and systematic sampling) in MRI-prebiopsy cohort. *no T4 cases in this cohort, see methods for how stage was assigned for clinical and MRI assignment. European Association of Urology (EAU), American Urological Association, Cambridge Prognostic Group (CPG)
| Â | Clinical stage and systematic biopsies | MRI stage and target systematic biopsies | Comparison | ||
|---|---|---|---|---|---|
n | Percentage (%) | n | Percentage (%) | (%) | |
Stage * | |||||
  T1-T2 | 263 | 71.1 | 234 | 63.2 | -7.8 |
  T3 | 107 | 28.9 | 136 | 36.8 | 7.8 |
Grade Group | |||||
  1 | 101 | 27.3 | 96 | 25.9 | -1.4 |
  2 | 123 | 33.2 | 133 | 35.9 | 2.7 |
  3 | 60 | 16.2 | 63 | 17.0 | 0.8 |
  4 | 13 | 3.5 | 17 | 4.6 | 1.1 |
  5 | 57 | 15.4 | 61 | 16.5 | 1.1 |
  Benign | 16 | 4.3 | - | - | -4.3 |
EAU (Cancers only) | (n = 354) | (n = 370) |  | ||
Low risk | 67 | 18.9 | 66 | 17.8 | -1.1 |
Intermediate risk | 155 | 43.8 | 143 | 38.7 | -5.1 |
High | 132 | 37.3 | 161 | 43.5 | 6.2 |
AUA (Cancers only) | |||||
  Low risk | 67 | 18.9 | 66 | 17.8 | -1.1 |
  Favourable intermediate risk | 86 | 24.3 | 78 | 21.1 | -3.2 |
  Unfavourable intermediate risk | 69 | 19.5 | 65 | 17.6 | -1.9 |
  High risk | 132 | 37.3 | 161 | 43.5 | 6.2 |
CPG (Cancers only) | |||||
  1 | 67 | 18.9 | 66 | 17.8 | -1.1 |
  2 | 86 | 24.3 | 78 | 21.1 | -3.2 |
  3 | 69 | 19.5 | 65 | 17.6 | -1.9 |
  4 | 64 | 18.1 | 83 | 22.4 | 4.3 |
  5 | 68 | 19.2 | 78 | 21.1 | 1.9 |